These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

450 related items for PubMed ID: 29673132

  • 1. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram.
    Vieta E, Sluth LB, Olsen CK.
    J Affect Disord; 2018 Feb; 227():803-809. PubMed ID: 29673132
    [Abstract] [Full Text] [Related]

  • 2. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
    Baune BT, Sluth LB, Olsen CK.
    J Affect Disord; 2018 Mar 15; 229():421-428. PubMed ID: 29331703
    [Abstract] [Full Text] [Related]

  • 3. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine.
    Nierenberg AA, Loft H, Olsen CK.
    J Affect Disord; 2019 May 01; 250():35-42. PubMed ID: 30826492
    [Abstract] [Full Text] [Related]

  • 4. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.
    Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS.
    Neuropsychopharmacology; 2015 Jul 01; 40(8):2025-37. PubMed ID: 25687662
    [Abstract] [Full Text] [Related]

  • 5. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
    Jacobsen PL, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH.
    J Sex Med; 2015 Oct 01; 12(10):2036-48. PubMed ID: 26331383
    [Abstract] [Full Text] [Related]

  • 6. Validation of the University of California San Diego Performance-based Skills Assessment (UPSA) in major depressive disorder: Replication and extension of initial findings.
    Christensen MC, Sluth LB, McIntyre RS.
    J Affect Disord; 2019 Feb 15; 245():508-516. PubMed ID: 30439678
    [Abstract] [Full Text] [Related]

  • 7. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR, Jacobsen PL, Chen Y.
    Curr Med Res Opin; 2013 Mar 15; 29(3):217-26. PubMed ID: 23252878
    [Abstract] [Full Text] [Related]

  • 8. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.
    Christensen MC, Loft H, McIntyre RS.
    J Affect Disord; 2018 Feb 15; 227():787-794. PubMed ID: 29689693
    [Abstract] [Full Text] [Related]

  • 9. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram.
    Levada OA, Troyan AS.
    J Affect Disord; 2019 May 01; 250():114-122. PubMed ID: 30852363
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder.
    McIntyre RS, Florea I, Tonnoir B, Loft H, Lam RW, Christensen MC.
    J Clin Psychiatry; 2017 Jan 01; 78(1):115-121. PubMed ID: 27780334
    [Abstract] [Full Text] [Related]

  • 11. Using self-reported vocational functioning measures to identify employed patients with impaired functional capacity in major depressive disorder.
    Murthy NV, Xu R, Zhong W, Harvey PD.
    J Affect Disord; 2020 Jan 01; 260():550-556. PubMed ID: 31539692
    [Abstract] [Full Text] [Related]

  • 12. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder.
    Inoue T, Sasai K, Kitagawa T, Nishimura A, Inada I.
    Psychiatry Clin Neurosci; 2020 Feb 01; 74(2):140-148. PubMed ID: 31725942
    [Abstract] [Full Text] [Related]

  • 13. A Network Meta-Analysis Comparing Effects of Various Antidepressant Classes on the Digit Symbol Substitution Test (DSST) as a Measure of Cognitive Dysfunction in Patients with Major Depressive Disorder.
    Baune BT, Brignone M, Larsen KG.
    Int J Neuropsychopharmacol; 2018 Feb 01; 21(2):97-107. PubMed ID: 29053849
    [Abstract] [Full Text] [Related]

  • 14. Distinct association of plasma BDNF concentration and cognitive function in depressed patients treated with vortioxetine or escitalopram.
    Sagud M, Nikolac Perkovic M, Dvojkovic A, Jaksic N, Vuksan-Cusa B, Zivkovic M, Kusevic Z, Mihaljevic-Peles A, Pivac N.
    Psychopharmacology (Berl); 2021 Jun 01; 238(6):1575-1584. PubMed ID: 33560444
    [Abstract] [Full Text] [Related]

  • 15. Vortioxetine: A Review in Cognitive Dysfunction in Depression.
    Frampton JE.
    Drugs; 2016 Nov 01; 76(17):1675-1682. PubMed ID: 27807822
    [Abstract] [Full Text] [Related]

  • 16. Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder.
    Thase ME, Danchenko N, Brignone M, Florea I, Diamand F, Jacobsen PL, Vieta E.
    Eur Neuropsychopharmacol; 2017 Aug 01; 27(8):773-781. PubMed ID: 28663124
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV.
    Clin Ther; 2007 Nov 01; 29(11):2319-32. PubMed ID: 18158074
    [Abstract] [Full Text] [Related]

  • 18. Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder.
    Nishimura A, Aritomi Y, Sasai K, Kitagawa T, Mahableshwarkar AR.
    Psychiatry Clin Neurosci; 2018 Feb 01; 72(2):64-72. PubMed ID: 28858412
    [Abstract] [Full Text] [Related]

  • 19. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L.
    Int J Clin Pract; 2014 Jan 01; 68(1):60-82. PubMed ID: 24165478
    [Abstract] [Full Text] [Related]

  • 20. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L, Andersen HF, Reines EH.
    Curr Med Res Opin; 2005 Oct 01; 21(10):1659-68. PubMed ID: 16238906
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.